Quarterly report pursuant to Section 13 or 15(d)

Segment Information

v3.20.2
Segment Information
9 Months Ended
Jul. 31, 2020
Segment Reporting [Abstract]  
Segment Information

10. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) our legacy Patent Licensing activities. The following represents selected financial information for our segments for the three and nine months ended July 31, 2020 and 2019 and as of July 31, 2020 and October 31, 2019:

 

    For the Three Months Ended
July 31,
    For the Nine Months Ended
July 31,
 
    2020     2019     2020     2019  
Net Loss:                                
CAR-T Therapeutics   $ (402,223 )   $ (723,128 )   $ (1,527,586 )   $ (4,240,347 )
Cancer Vaccines     (172,881 )     (573,005 )     (538,748 )     (573,005 )
Anti-Viral Therapeutics     (268,704 )     -       (578,208 )     -  
Cancer Diagnostics     (1,727,256 )     (876,667 )     (5,196,929 )     (3,929,021 )
Patent Licensing     (5,723 )     6,752       (9,881 )     (965,218 )
Total   $ (2,576,787 )   $ (2,166,048 )   $ (7,851,352 )   $ (9,707,591 )
                                 
Total operating costs and expenses   $ 2,584,053     $ 2,184,412     $ 7,884,059     $ 10,011,374  
Less non-cash share-based compensation     (1,041,799 )     (830,898 )     (3,173,219 )     (4,902,512 )
Operating costs and expenses excluding non-cash share-based compensation   $ 1,542,254     $ 1,353,514     $ 4,710,840     $ 5,108,862  
Operating costs and expenses excluding non-cash share based compensation:                                
CAR-T Therapeutics   $ 182,007     $ 442,621     $ 752,170     $ 1,688,301  
Cancer Vaccines     70,061       407,010       235,391       407,010  
Anti-Viral Therapeutics     149,075       -       370,093       -  
Cancer Diagnostics     1,136,629       487,169       3,345,441       1,905,137  
Patent Licensing     4,482       16,714       7,745       1,108,414  
Total   $ 1,542,254     $ 1,353,514       4,710,840     $ 5,108,862  

 

    July 31,
2020
    October 31,
2019
 
Total assets:                
CAR-T Therapeutics   $ 4,110,341     $ 2,382,460  
Cancer Vaccines     1,575,525       489,881  
Anti-Viral Therapeutics     3,349,814       -  
Cancer Diagnostics     78,723       3,119,246  
Patent Licensing     247,378       302,106  
Total   $ 9,361,781     $ 6,293,693  

 

Operating costs and expenses excluding non-cash share-based compensation expense is the measurement the chief operating decision-maker uses in managing the enterprise.